Protara Therapeutics, Inc. (TARA)
NGM · Healthcare · Biotechnology
$3.81
-3.30%
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
Market Cap
$214.1M
Shares Outstanding
56.2M
Exchange
NGM
Currency
USD
About Protara Therapeutics, Inc.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -16.6M | -14.8M | -19.1M | -19.6M |
| Net Income | -15.0M | -13.3M | -17.3M | -17.8M |
| Diluted EPS | $-0.35 | $-0.31 | $-0.37 | $-0.31 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -37.5M | -43.6M | -49.2M | -64.5M |
| Net Income | -66.0M | -40.4M | -44.6M | -57.4M |
| Diluted EPS | $-5.86 | $-3.57 | $-2.17 | $nan |